INOVIO PHARMACEUTICALS, INC. Unrealized Gain (Loss) on Investments
INOVIO PHARMACEUTICALS, INC. (INO) reported Unrealized Gain (Loss) on Investments of -$178.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $454.00K, a 39.14% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$632.00K.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $14.00K, a 93.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $220.00K, a 84.29% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for fiscal 2025 was -$720.00K.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for fiscal 2024 was -$1.90M.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for fiscal 2023 was -$3.90M.
- INOVIO PHARMACEUTICALS, INC. unrealized gain (loss) on investments for fiscal 2022 was -$8.70M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$178.00K 10-Q · filed 2026-08-12 | -$164.00K derived: sum of 3 quarters · filed 2026-08-12 | $56.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$632.00K 10-Q · filed 2026-05-13 | -$618.00K derived: sum of 2 quarters · filed 2026-05-13 | -$398.00K derived: sum of 3 quarters · filed 2026-05-13 | $348.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $234.00K derived: sum of 2 quarters · filed 2026-03-12 | $980.00K derived: sum of 3 quarters · filed 2026-03-12 | -$720.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $966.00K derived: sum of 2 quarters · filed 2025-11-10 | -$734.00K 10-Q · filed 2025-11-10 | -$534.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | $746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$954.00K 10-Q · filed 2025-08-12 | -$754.00K derived: sum of 3 quarters · filed 2025-08-12 | $646.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | -$1.70M 10-Q · filed 2025-05-13 | -$1.50M derived: sum of 2 quarters · filed 2025-05-13 | -$100.00K derived: sum of 3 quarters · filed 2025-05-13 | -$200.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.60M derived: sum of 2 quarters · filed 2025-03-18 | $1.50M derived: sum of 3 quarters · filed 2025-03-18 | -$1.90M 10-K · filed 2025-03-18 |
| 2024-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.30M derived: sum of 2 quarters · filed 2024-11-14 | -$2.10M 10-Q · filed 2024-11-14 | -$100.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.50M 10-Q · filed 2024-08-08 | -$1.50M derived: sum of 3 quarters · filed 2024-08-08 | -$1.80M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | -$3.40M 10-Q · filed 2024-05-13 | -$1.40M derived: sum of 2 quarters · filed 2024-05-13 | -$1.70M derived: sum of 3 quarters · filed 2024-05-13 | -$800.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $1.70M derived: sum of 2 quarters · filed 2024-03-06 | $2.60M derived: sum of 3 quarters · filed 2024-03-06 | -$3.90M 10-K · filed 2024-03-06 |
| 2023-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $600.00K derived: sum of 2 quarters · filed 2023-11-09 | -$5.90M 10-Q · filed 2023-11-09 | -$8.80M derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$5.60M 10-Q · filed 2023-08-09 | -$8.50M derived: sum of 3 quarters · filed 2023-08-09 | -$9.80M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | -$6.50M 10-Q · filed 2023-05-10 | -$9.40M derived: sum of 2 quarters · filed 2023-05-10 | -$10.70M derived: sum of 3 quarters · filed 2023-05-10 | -$12.30M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$4.20M derived: sum of 2 quarters · filed 2023-03-01 | -$5.80M derived: sum of 3 quarters · filed 2023-03-01 | -$8.70M 10-K · filed 2023-03-01 |
| 2022-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$2.90M derived: sum of 2 quarters · filed 2022-11-08 | -$5.80M 10-Q · filed 2022-11-08 | -$6.29M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$4.50M 10-Q · filed 2022-08-09 | -$4.99M derived: sum of 3 quarters · filed 2022-08-09 | -$5.05M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | -$2.90M 10-Q · filed 2022-05-10 | -$3.39M derived: sum of 2 quarters · filed 2022-05-10 | -$3.46M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2021-12-31 | -$489.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$555.00K derived: sum of 2 quarters · filed 2022-03-01 | -$766.00K 10-K · filed 2022-03-01 | |
| 2021-09-30 | -$66.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$277.00K 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | -$211.00K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |